MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Resistance training in patients with Parkinson’s disease: a systematic review and meta-analysis

    R. Gollan, M. Ernst, E. Lieker, J. Caro-Valenzuela, I. Monsef, A. Dresen, M. Roheger, N. Skoetz, E. Kalbe, AK. Folkerts (Cologne, Germany)

    Objective: To analyze the effects of resistance training (RT) on motor- and non-motor outcomes in patients with Parkinson's disease (PD) compared to passive and physically…
  • 2022 International Congress

    The results of DBS in patients with Parkinson’s disease for 10 years in Belarus

    A. Buniak, V. Alexeyevets, S. Likhachev (Minsk, Belarus)

    Objective: To study the efficiency and SE of DBS in PD patients in Republican Research and Clinical Center of Neurology and Neurosurgery in Belarus for…
  • 2022 International Congress

    GDNF Gene Therapy for Parkinson’s Disease (PD): Preliminary Safety and Clinical Findings from a Phase Ib Study

    A. van Laar, C. Christine, A. Merola, N. Phielipp, B. Elder, P. Larson, N. Stoicea, W. San Sebastian, M. Fiandaca, A. Kells, K. Bankiewicz (Research Triangle Park, USA)

    Objective: Assess the safety and tolerability of intraputaminal AAV2-GDNF in mild to moderate PD Background: Glial cell line-derived neurotrophic factor (GDNF) is critical for dopaminergic…
  • 2022 International Congress

    Nocturnal attacks of abnormal sleep behaviors and abnormal movements induced by insulin: A case report

    S. El-Jaafary (Cairo, Egypt)

    Objective: To report a case of abnormal sleep behavior associated with hypoglycemia induced by insulin. Background: Hypoglycemia is a serious condition that can be manifested…
  • 2022 International Congress

    Levodopa-carbidopa intestinal gel infusion and long-term tolerability in Parkinson’s: multicentre, international 13-year follow-up data

    V. Leta, L. Batzu, L. Williams, S. Waller, F. Garri, K. Rukavina, M. Parry, S. Jones, J. Griffith, N. Jeyakumar, M. Scharfenort, P. Odin, V. Metta, G. Chung-Faye, P. Dubois, T. Marshall, A. Zecchinelli, F. Del Sorbo, V. Viljaharju, E. Pekkonen, A. Antonini, V. Fung, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To evaluate the long-term range and nature of Levodopa-carbidopa intestinal gel (LCIG) infusion-related complications in people with Parkinson’s (PwP). Background: LCIG infusion is an…
  • 2022 International Congress

    Automatic Speech Recognition for speech therapy in a Parkinson’s disease patient

    A. Nuzzi (Bari, Italy)

    Objective: The aim of the present study was to examine the Automatic Speech Recognition (ASR) technology as a useful approach to enhance the speech intelligibility…
  • 2022 International Congress

    Longitudinal assessment of quality of life in early Parkinson’s disease: 5-year follow up study

    I. Stankovic, T. Pekmezovic, V. Markovic, N. Dragasevic, I. Petrovic, M. Svetel, V. Kostic (Belgrade, Serbia)

    Objective: To determine changes in HR-QoL in early PD patients during a 5-year follow up period. Background: There is limited evidence on longitudinal changes in…
  • 2022 International Congress

    Lentiform fork sign and Wilson Disease

    JL. Freitas, MS. Rocha, PC. Matos, I. Torres, L. Corazza, JF. Tasch (São Paulo, Brazil)

    Objective: First description of lentiform fork sign in patients with the diagnosis of Wilson disease. Background: Lentiform fork sign is a rare neuroradiological sign characterized…
  • 2022 International Congress

    Effects of Once-Daily Opicapone 50 mg on COMT activity: A Pooled Post-hoc Analysis of Two Phase 1 Studies

    G. Loewen, A. Vijan, K. Olson, T. O'Reilly, G. Liang, O. Klepitskaya (San Dieg, USA)

    Objective: To assess the effects of opicapone (OPC) 50 mg adjunct to carbidopa/levodopa (CD/LD) on catechol-O-methyltransferase (COMT) activity by participants’ baseline characteristics using pooled data…
  • 2022 International Congress

    Impact of COVID-19 in Parkinson disease: preliminary analysis from a survey performed in a Peruvian PD cohort.

    E. Sarapura-Castro, D. Rivera-Asencios, M. Illanes-Manrique, A. Rivera-Valdivia, M. Inca-Martinez, K. Mejia-Rojas, J. Rios-Pinto, A. Medina-Colque, I. Cornejo-Herrera, E. Ochoa-Valle, C. Cosentino, I. Mata, M. Cornejo-Olivas (Lima, Peru)

    Objective: To analyze the impact of COVID-19 in Parkinson cases and healthy controls from a Peruvian population. Background: The COVID-19 pandemic have a profound impact…
  • « Previous Page
  • 1
  • …
  • 131
  • 132
  • 133
  • 134
  • 135
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley